Ischemic stroke is a leading cause of death and disability worldwide, with many patients experiencing poor outcomes despite ...

Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when ...

Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that the U.S. Food and Drug Administration has granted Fast ...

CHI St. Alexius Dickinson earns American Heart Association’s Rural Stroke Gold Achievement Award, recognizing the hospital’s excellence in treating strokes across southwest North Dakota.

Just 14 patients need screening with extended CT angiography to find one clot, according to the DAYLIGHT study, improving ...

A groundbreaking study from the University of Cambridge reveals a new drug that can significantly reduce brain damage caused ...

UT Dell Medical School study helps solve question of when to start blood thinners after a stroke in someone with AFib.

DelveInsight's Ischemic Stroke pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Ischemic Stroke treatment.

There are similar outcomes between patients transported by EMS and mobile stroke units, but mobile stroke units have more favorable time metrics.

Sovateltide, a potential first-in-class, highly selective endothelin-B (ETB) receptor agonist, has previously demonstrated significant improvement in stroke patients compared to standard of care in a ...

US FDA grants fast track designation to Revalesio’s lead investigational therapy, RNS60 to treat acute ischemic stroke: Tacoma, Washington Saturday, August 2, 2025, 15:00 Hrs [I ...